In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry

Quantitation of circulating tumor cells (CTCs) constitutes an emerging tool for the diagnosis and staging of cancer, assessment of response to therapy, and evaluation of residual disease after surgery. Unfortunately, no existing technology has the sensitivity to measure the low numbers of tumor cells (<1 CTC per ml of whole blood) that characterize minimal levels of disease. We present a method, intravital flow cytometry, that noninvasively counts rare CTCs in vivo as they flow through the peripheral vasculature. The method involves i.v. injection of a tumor-specific fluorescent ligand followed by multiphoton fluorescence imaging of superficial blood vessels to quantitate the flowing CTCs. Studies in mice with metastatic tumors demonstrate that CTCs can be quantitated weeks before metastatic disease is detected by other means. Analysis of whole blood samples from cancer patients further establishes that human CTCs can be selectively labeled and quantitated when present at ≈2 CTCs per ml, opening opportunities for earlier assessment of metastatic disease.

[1]  P. Low,et al.  Evaluation of Folate Conjugate Uptake and Transport by the Choroid Plexus of Mice , 2003, Pharmaceutical Research.

[2]  B R Masters,et al.  Two-photon excitation fluorescence microscopy. , 2000, Annual review of biomedical engineering.

[3]  Beop-Min Kim,et al.  Simple high-speed confocal line-scanning microscope. , 2005, Optics express.

[4]  P. Low,et al.  Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Charles P. Lin,et al.  Real-time Detection of Circulating Apoptotic Cells by in Vivo Flow Cytometry , 2005, Molecular imaging.

[6]  Tayyaba Hasan,et al.  Flow Cytometry : A New Method for Enumerating Circulating Cancer Cells , 2004 .

[7]  P. Kenemans,et al.  Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma‐Associated Antigens , 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[8]  S. Achilefu,et al.  Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. , 2001, Journal of biomedical optics.

[9]  Philip S Low,et al.  Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. , 2004, American journal of physiology. Cell physiology.

[10]  Charles P. Lin,et al.  In vivo flow cytometer for real-time detection and quantification of circulating cells. , 2004, Optics letters.

[11]  P. Saigo,et al.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. , 1993, The American journal of pathology.

[12]  T. Gómez-Cía,et al.  Flow changes in forearm arteries after elevating the radial forearm flap: prospective study using color duplex imaging. , 1999, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[13]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[14]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[15]  P. Low,et al.  Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery , 2004, Molecular Pharmacology.

[16]  Jing Yong Ye,et al.  Multiphoton in vivo flow cytometry , 2005, (CLEO). Conference on Lasers and Electro-Optics, 2005..

[17]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[18]  I. Rosenberg,et al.  Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. , 2007, The American journal of clinical nutrition.

[19]  J. Reddy,et al.  Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  David A. Benaron,et al.  The Future of Cancer Imaging , 2004, Cancer and Metastasis Reviews.

[21]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[22]  J. Reddy,et al.  Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. , 2002, Bioconjugate chemistry.

[23]  B. Molnár,et al.  Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[25]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[26]  W. Webb,et al.  Nonlinear magic: multiphoton microscopy in the biosciences , 2003, Nature Biotechnology.

[27]  P. Low,et al.  T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[29]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Low,et al.  Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors , 2002, Cancer Immunology, Immunotherapy.

[31]  M. Pomper,et al.  Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer , 2005, Clinical Cancer Research.

[32]  Z. Hall Cancer , 1906, The Hospital.

[33]  V. Zurawski,et al.  Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.

[34]  J. Scott,et al.  Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. , 1996, Blood.

[35]  M. Benninger,et al.  Micrometastatic tumor detection in patients with head and neck cancer: a preliminary report. , 2002, Archives of otolaryngology--head & neck surgery.

[36]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Wilson,et al.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.

[38]  R. Wendt,et al.  Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.